Gossamer Bio (GOSS) shares are in focus after the company detailed plans to submit an NDA for seralutinib in pulmonary ...
Hopie Dope Official on MSN
First yarn haul featuring Akari and Gossamer Lace
Explore a colorful first yarn haul featuring Akari and Gossamer Lace. Discover premium fibers, unique textures, and fresh ...
The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...
Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Gossamer Bio has experienced numerous ups and downs over the years, including a clinical setback and significant staff reductions. Now, as it pursues potential approval for a heart drug, the company ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
- Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups - - Statistically significant ...
Shelia Gujrathi is the CEO and cofounder of Gossamer Bio, which went public on February 8, raising over $270 million. When Celgene bought Receptos in 2015, Dr. Sheila Gujrathi, who was chief medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results